$$ Grant Life Sciences! Volumen lügt nicht! $$

das Deine Erklärungen bzw Ausreden einfach lächerlich sind? tststs *kopfschüttel*  

Schaut nur ..  

auf's Klo muss.;-))

Aber das ist definitiv.  

@ Obligator:
Ich glaubt ich habe dein Anliegen erkannt. Du willst uns mit aller Kraft von der Aktie überzeugen. Is ja auch ok und lukrativ(wenn man´s richtig anstellt).
Aber da mußt du die 3 PGR´s( Pushergrundregeln) befolgen:

1: Blumige Sprache: Deine Postings müssen lang und ausschweifend sein. Philosophiere über Marktchancen, fast monopolistische Marktanteile und darüber, dasss mindestens jeder Mensch auf der Welt in 2 Wochen die Aktie haben will.
Dabei möglichst viele Fremdwort, ABkürzungen etc. benutzen...

2:Grafiken: Gerne gesehen sind auch aufwendige Chartgrafiken.
Setze am besten den Kursverlauf in Beziehung zu allen Indizies die du finden kannst.
Die Deutung natürlich nicht vergessen. Da eh nur 1/3 der Nutzer hier nen Chart halbwegs richitg lesen kann, musst du das übernehmen. Dabei wieder Punkt 1 beachten. Gerne genommene Vokalben in diesem Zusammenhang sind: u.a. Bodenbildung,nachhaltiger Wiederstand bei x € etc.

3: Wiederholungen: Du mußt möglichst oft in unterschiedlichen Variationen über die Aktie berichten bzw. News ankündigen. Dabei hilft eine doppelID ungemein. Du kannst dich damit quasi selbst von der Sinnhaftigkeit der Geldanlage überzeugen.

So, wenn du diese drei Grundregeln befolgst, kann eigentlich nichts mehr schiefgehen.

 

Litening genau das versuche ich ja schon die ganze Zeit bei Grant Life, um die negative Stimmung etwas aufzumuntern.

Das mit dem Puschen stimmt nicht ganz, was ich jetzt sage dazu stehe ich auch:
Wo ich investiert bin, an diese Aktien glaube ich auch (dazu gehört halt etwas Geduld in schweren Phasen, ähnlich der Frauen).
Es muss ja keiner auf meine Positive Schreie reagieren, denn schließlich äußere ich nur meine Meinung ;-)
 

aber da hat er wohl recht -- die pusherregeln musst du beachten -- es geht nicht anders wenn du erfogreich sein willst und die anderen für dumm verkaufen möchtest -- also.

1. blumige sprache
2. charts
3. gaanz viel schreiben -- 2te ID etc etc

dann klappts auch mit der kohle

find ich ja wirklich süss und knuffig -- aber du musst das wirklich so machen wie litning das geschrieben hat -- ansonsten seh ich rot für dein konto

du machst das schon  

Ich wollte ja eigentlich kein Komentar mehr abgeben, um zu vermeiden wieder als Puscher bezeichnet zu werden (leider haben sind hier viele besserwiesser), aber das war eine gute gelegenheit zum nachkaufen ;-)  

Es heißt "Besserwisser""Pusher(weil Englisch)" usw.!
Aber achja ...ich weiß, Du wolltest nur mal testen wie es um die Grammatik in diesem Forum steht.....

bla bla blubb  

Wie es scheint sind manche nicht zu retten, na dann Prost!  

 

Schade, aber wenigstens bin ich treu meinem Bauchgefühl (bezieht sich auf heute Morgen).  

Betrieft vorallem die jenigen, die sich ohne einen wahren Grund mit pusher um sich schmeißen ;-)  

"Betrieft vorallem die jenigen, die sich ohne einen wahren Grund mit pusher um sich schmeißen ;-)"

Dazu fällt mir ein Spruch ein: "Gaufst du dich Duden, machen du fil wenige Vela un Krammatik wird auch bessa"

Aber mal ehrlich Obligator. Was willst du uns denn mit diesem Satz sagen?
Ich versteh´s echt nicht. Also schon rein vom Sinn her, über Inhalt wollen wir mal gar nicht reden...  

mal unter uns..... das war bestimmt nur wieder einer seiner Tests..um das Niveau bzw den Intellekt hier im Forum zu testen. ;))


Schade das man bei oligator nicht komplett wegzappen kann wie bei den ganzen billigen Talkshows...sind sich im übrigen sehr ähnlich, wie ich finde ...;)



Aber seine Aussagen sind teilweise schon amüsant.....gleich bricht die Decke...LOL
wenn der so weitermacht, brech ich auf die Decke  

Ihr seid echte Spaßvogels macht weiter so.
Leider wird Ihr Geldbeutel davon nicht dicker, wenn man auch weiterhin Stur bleibt und versucht die anderen nur schlecht dar zu stellen, na ja jedem halt seine, ich weiß ist schwierig seine Fehler zuzugeben, z.b das die anderen auch recht haben können!
Grammatikfehler von mir aus, letztendlich zählt hier nur wer zuletzt lacht lacht am besten ;-)
 

Grant Life Sciences (\\\'Grant\\\') extends to Oct. 15, 2006, a Memorandum of Understanding with Diagnostic Technologies Ltd. (\\\'DTL\\\') to develop and commercialize Grant\\\'s cervical cancer-diagnostic platform


2006-10-03 09:39 ET - News Release


LOS ANGELES -- (Business Wire)

Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced
today that it has extended to Oct. 15, 2006, a Memorandum of
Understanding (MOU) with Israel-based Diagnostic Technologies Ltd.
(DTL) related to Grant\\\'s cervical cancer-diagnostic technology (U.S.
Patent No. 6,743,593). Assuming acceptable due diligence by DTL, the
definitive Licensing Agreement would include an upfront licensing fee
of $250,000 paid to Grant. In addition, DTL would conduct all product
development at its own cost, including clinical trials, associated
with the commercialization of products developed from Grant\\\'s cervical
cancer-diagnostic technology. Upon commercialization, DTL would pay
Grant an ongoing royalty on sales of the products developed, according
to the definitive Licensing Agreement.

The extension of the MOU between Grant and DTL has been made
necessary because DTL\\\'s business activities were significantly
hindered as a result of the 2006 Israel/Lebanon conflict, which
occurred between July 12 and August 14, 2006.

The definitive Licensing Agreement is expected to be signed by DTL
following appropriate due diligence and a feasibility test. Upon
signing, DTL will immediately assume all of the costs associated with
turning Grant\\\'s core technology related to cervical-cancer diagnostics
into a commercially viable product. The diagnostic product based on
Grant\\\'s technology will augment and complement DTL\\\'s suite of
diagnostics targeted at the women\\\'s health market.

"We remain very excited about our potential partnership with DTL,
as it will represent one of the most important milestones in the
evolution of our company once it is finalized," said Hun-Chi Lin,
Ph.D., Grant\\\'s President and Chief Scientist. "We believe a two-month
extension of the due diligence period is quite fair to DTL, given the
hardships DTL suffered as a result of the recent war between Israel
and Lebanon."

"A partnership with DTL would afford Grant the opportunity to
focus efforts on ramping up revenues from sales in Asia of our rapid
AccuDx tests for Malaria and Dengue Fever and other deadly diseases,"
added Dr. Lin. "We expect to continue to drive new-business
development efforts related to this product line throughout Asia.
Certainly, our recent announcement that Grant has received a purchase
order from an arm of the Indian government for two million of our
point-of-care, \\\'rapid\\\' malaria tests, to be delivered by year-end,
bears strong testimony to the viability of our strategy."

About Diagnostic Technologies Ltd. (DTL)

DTL, based in Haifa, Israel, is a public company that has licensed
from Technion a technology for the prediction of the risk of
preeclampsia in maternal serum. According to the CDC, preeclampsia
affects five to seven percent of all pregnant women and can result in:
loss of life; blindness; motor and mental disorders or premature
newborns; pregnancy hypertension; and kidney, liver and cardiovascular
malfunctioning. It is estimated that nearly $30 billion is spent today
in healthcare costs to treat women with preeclampsia and their
newborns. DTL\\\'s simple blood test for the early prediction of
preeclampsia is now in clinical trials. TEUZA, an Israeli venture
fund, is the major investor in the Company. On Jan. 31, 2006,
PerkinElmer, Inc., announced that it had secured the exclusive global
rights to the test for identifying patients at risk for preeclampsia
developed by DTL.

About Grant Life Sciences Inc.

Grant Life Sciences Inc. (OTC BB:GLIF.OB), a development stage
company, engages in the research, development, marketing, and sale of
diagnostic kits for the screening, monitoring, and diagnosis of
diseases with emphasis on women\\\'s health, infectious diseases, and
cancers.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters
discussed in this press release are "forward-looking statements" that
involve a number of risks and uncertainties. The actual future results
of Grant Life Sciences could differ significantly from those
statements. Factors that could cause actual results to differ
materially include risks and uncertainties such as the inability to
finance the company\\\'s operations or expansion, inability to hire and
retain qualified personnel, changes in the general economic climate,
including rising interest rates and unanticipated events such as
terrorist activities, results of clinical trials, and market
acceptance of the Company\\\'s products. In some cases, "forward-looking
statements" can be identified by terminology such as "may," "will,"
"should," "expect," "plan," "anticipate," "believe," "estimate,"
"predict," "potential" or "continue," or other comparable terminology.
Although Grant Life Sciences believes that the expectations reflected
in the "forward-looking" statements are reasonable, such statements
should not be regarded as a representation by the Company, or any
other person, that such "forward-looking statements" will be achieved.
Grant Life Sciences undertakes no duty to update any of the
"forward-looking statements," whether as a result of new information,
future events or otherwise. In light of the foregoing, readers are
cautioned not to place undue reliance on such "forward-looking
statements." For further risk factors associated with our Company,
review our SEC filings.
Contacts:

Grant Life Sciences Inc.
Don Rutherford, 949-521-1232

Source: Grant Life Sciences Inc.
 

 

wollten wir nicht alle schon mal auf die Decke brechen?:-)  

 

Doch wann knallt es hier richtig nach oben?  

 

Press Release Source: Grant Life Sciences Inc.


Grant Life Sciences Enters into Memorandum of Understanding (MOU) with i+MED Laboratories Co. Ltd. to Distribute i+MED\'s Point-of-Care Rapid Diagnostic Tests Via Grant\'s Established Marketing Channels
Wednesday October 11, 9:00 am ET


LOS ANGELES--(BUSINESS WIRE)--"This is the third partnership we have announced in recent weeks, bearing strong testimony that we are aggressively executing Grant\'s new corporate strategy, which includes driving the sales of our partners\' products through our own established, significant marketing channels."





Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences

Grant Life Sciences Inc. (OTC BB: GLIF - News) announced today that it has signed a Memorandum of Understanding (MOU) with Thailand-based i+MED Laboratories Co. Ltd. to distribute i+MED\'s point-of-care rapid diagnostic tests via Grant\'s established marketing channels in India, Taiwan, Indonesia, Mexico, Middle East and Africa and expand into other countries later.

The i+MED product portfolio to be distributed by Grant includes, but is not limited to, the following rapid tests: drugs of abuse, pregnancy, and infectious disease product lines.

"This is the third partnership we have announced in recent weeks, bearing strong testimony that we are aggressively executing Grant\'s new corporate strategy, which includes driving the sales of our partners\' products through our own established, significant marketing channels," said Hun-Chi Lin, Ph.D., Grant\'s President and Chief Scientist.

About i+MED Laboratories

Founded in 2001, i+MED Laboratories Co. Ltd. (www.imed.co.th) is one of the leading diagnostics companies in Thailand. The company, which develops, manufactures and distributes high-quality \'rapid\' tests for Asian markets, is 46 percent owned by the Thai government\'s SME Venture Capital Fund.

About Grant Life Sciences

Grant Life Sciences Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women\'s health, infectious diseases, and cancers.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company\'s operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company\'s products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.



Contact:
Grant Life Sciences Inc.
Don Rutherford, 949-521-1232
CFO

--------------------------------------------------
Source: Grant Life Sciences Inc.
 

 

Also mein Businessenglisch is ja nicht das beste aber hab ich die Meldung richtig verstanden , dass GLS ne neue partnership mit I+MEd hat...

 

Unfassbar! 0,10 $